Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1990 1
1998 1
2005 1
2008 1
2009 4
2012 1
2014 1
2015 1
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Tofacitinib versus methotrexate in rheumatoid arthritis.
Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF; ORAL Start Investigators. Lee EB, et al. N Engl J Med. 2014 Jun 19;370(25):2377-86. doi: 10.1056/NEJMoa1310476. N Engl J Med. 2014. PMID: 24941177 Free article. Clinical Trial.
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B; ORAL Standard Investigators. van Vollenhoven RF, et al. N Engl J Med. 2012 Aug 9;367(6):508-19. doi: 10.1056/NEJMoa1112072. N Engl J Med. 2012. PMID: 22873531 Free article. Clinical Trial.
Reply.
Pope JE, Rothfield NF, Ramsey-Goldman R, Douglas Smith C, Bernatsky SR, Furie RA, Hudson M, Burgos-Vargas R, Senécal JL, Inanç M, van Vollenhoven RF, Chandran V, Nash PT, Muangchan C. Pope JE, et al. Among authors: nash pt. Arthritis Care Res (Hoboken). 2016 Jul;68(7):1053-4. doi: 10.1002/acr.22777. Arthritis Care Res (Hoboken). 2016. PMID: 26555102 Free article. No abstract available.
Tumour necrosis factor inhibitors.
Nash PT, Florin TH. Nash PT, et al. Med J Aust. 2005 Aug 15;183(4):205-8. doi: 10.5694/j.1326-5377.2005.tb06998.x. Med J Aust. 2005. PMID: 16097922 Review.
Does Lyme disease exist in Australia?
Nash PT. Nash PT. Med J Aust. 1998 May 18;168(10):479-80. doi: 10.5694/j.1326-5377.1998.tb141406.x. Med J Aust. 1998. PMID: 9631669 No abstract available.
Treatment Algorithms in Systemic Lupus Erythematosus.
Muangchan C, van Vollenhoven RF, Bernatsky SR, Smith CD, Hudson M, Inanç M, Rothfield NF, Nash PT, Furie RA, Senécal JL, Chandran V, Burgos-Vargas R, Ramsey-Goldman R, Pope JE. Muangchan C, et al. Among authors: nash pt. Arthritis Care Res (Hoboken). 2015 Sep;67(9):1237-1245. doi: 10.1002/acr.22589. Arthritis Care Res (Hoboken). 2015. PMID: 25777803 Free article.
Inappropriate prescribing for osteoporosis.
Seeman E, Kotowicz MA, Nash PT, Sambrook PN. Seeman E, et al. Among authors: nash pt. Med J Aust. 2009 Sep 21;191(6):355; author reply 355-6. doi: 10.5694/j.1326-5377.2009.tb02824.x. Med J Aust. 2009. PMID: 19769562 No abstract available.
Polyarthritis. A diagnostic approach.
Webb J, Nash PT. Webb J, et al. Among authors: nash pt. Aust Fam Physician. 1990 Oct;19(10):1533, 1536-7, 1540-2. Aust Fam Physician. 1990. PMID: 2248565 Review.
Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.
Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU; GO-FORWARD Study. Keystone EC, et al. Ann Rheum Dis. 2009 Jun;68(6):789-96. doi: 10.1136/ard.2008.099010. Epub 2008 Dec 9. Ann Rheum Dis. 2009. PMID: 19066176 Free PMC article. Clinical Trial.
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU; GO-AFTER study investigators. Smolen JS, et al. Lancet. 2009 Jul 18;374(9685):210-21. doi: 10.1016/S0140-6736(09)60506-7. Epub 2009 Jun 26. Lancet. 2009. PMID: 19560810 Clinical Trial.
12 results